|
Friday 31st October 2003 |
Text too small? |
The shares investors bought at $2.50 in September 2001 are trading at $1.86 but well above their low of $1.10 last year.
The company has benefited from an increase in patients opting for private medical and surgical attention as public hospitals grapple with unconscionable waiting lists.
It has made no secret of it also looking to benefit from an ageing population, pitting the business squarely in the healthcare sector.
Profit for the year ended March 31 increased 16% to $793,000 after absorbing $258,000 in unusual costs associated with a Securities Commission inquiry into the company's prospectus and listing.
Since then it has appointed former PricewaterhouseCoopers senior manager John Dixon as chief executive and has acquired local counterpart Bowen Hospital.
The improvement coincides with Sir Selwyn Cushing's family trust acquiring a 5% stake.
Wakefield will be looking to consolidate its gains while extracting all it can from the Bowen acquisition. The company is forecasting a "significant increase" in net profit for the 2004 year and should achieve that if patient numbers continue at present levels.
No comments yet
HGH - Heartland 2026 Annual General Meeting
WHS provides FY27 first quarter trading update
AIA - successfully completes new A$300 million AMTN issue
November 13th Morning Report
SPK - Response to open letter regarding FY26 financial statements
HGH - Update on proposed TSB transaction target completion date
MFT - Mainfreight Half Year Financial Results 30 September 2026
MCY - Executive leadership team changes
November 12th Morning Report
GTK - FY26 Investor Briefing Details